MedTrace Logo

Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)

NCT03708601 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2019-05-24

No results posted yet for this study

Summary

The registry study aims to determine serial biomarkers to prognosis of Essential Hypertension

Conditions

  • Essential Hypertension

Sponsors & Collaborators

  • Shanxi Medical University

    collaborator OTHER

  • Beijing Institute of Heart, Lung and Blood Vessel Diseases

    lead OTHER

Principal Investigators

  • Jie Du, PhD · The Key Laboratory of Remodeling-Related Cardiovascular Disease, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart,Lung and Blood Vessel Diseases

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-08
Primary Completion
2022-08-08
Completion
2022-08-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03708601 on ClinicalTrials.gov